全文获取类型
收费全文 | 55篇 |
免费 | 31篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 1篇 |
妇产科学 | 4篇 |
基础医学 | 2篇 |
口腔科学 | 6篇 |
临床医学 | 11篇 |
内科学 | 14篇 |
神经病学 | 2篇 |
特种医学 | 2篇 |
外科学 | 13篇 |
预防医学 | 8篇 |
药学 | 1篇 |
肿瘤学 | 5篇 |
出版年
2023年 | 2篇 |
2020年 | 9篇 |
2019年 | 2篇 |
2018年 | 5篇 |
2017年 | 11篇 |
2016年 | 5篇 |
2015年 | 10篇 |
2014年 | 6篇 |
2013年 | 3篇 |
2012年 | 1篇 |
2011年 | 2篇 |
2010年 | 3篇 |
2009年 | 5篇 |
2008年 | 3篇 |
2007年 | 4篇 |
2006年 | 6篇 |
2005年 | 1篇 |
2003年 | 1篇 |
2002年 | 1篇 |
2001年 | 1篇 |
1999年 | 1篇 |
1997年 | 2篇 |
1996年 | 1篇 |
1994年 | 1篇 |
排序方式: 共有86条查询结果,搜索用时 708 毫秒
31.
32.
33.
34.
Reversal of rocuronium‐induced neuromuscular blockade by sugammadex allows for optimization of neural monitoring of the recurrent laryngeal nerve 下载免费PDF全文
35.
36.
37.
ABSTRACT: The Canadian Maternity Experiences Survey provides a wealth of data on reproductive decision‐making, prenatal care and experiences of women during their pregnancies, intrapartum and postpartum experiences, as well as women’s mental health, social supports, and health behaviors. This population‐based representative sample survey, drawn from a sampling frame based on the Canadian Census for 2006, puts a human face on pregnancy, childbirth, postpartum maternal health, and parenting, and could serve as a model for similar data collection efforts in other countries. (BIRTH 35:4 December 2008) 相似文献
38.
Background
According to prior analyses, extended-release niacin/laropiprant (ERN/LRPT) consistently reduces low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) and increases high-density lipoprotein cholesterol (HDL-C) levels across a wide range of dyslipidemic patient subgroups.Objectives
This analysis examined ERN/LRPT’s consistency across four phase III, randomized, double-blind trials in improving other lipid/lipoprotein parameters associated with cardiovascular risk, across several key dyslipidemic patient subgroups.Methods
In three of the studies, the randomized population included patients with primary hypercholesterolemia or mixed hyperlipidemia; in the remaining study, the population included patients with type 2 diabetes mellitus. The lipid-altering consistency of ERN/LRPT’s efficacy was evaluated versus the predefined comparator (placebo or active control) among key subgroups of sex, race (White, non-White), region (US, ex-US), baseline age (<65 years, ≥65 years), use of statin therapy (yes, no), coronary heart disease (yes, no), risk status (low, multiple, high), and type of hyperlipidemia (primary hypercholesterolemia, mixed dyslipidemia), as well as across baseline LDL-C, HDL-C, and TG levels. The consistency of the treatment effects on lipoprotein(a) [Lp(a)], apolipoprotein B (ApoB), non-HDL-C, ApoA1, and ApoB/ApoA1 ratio was evaluated by examining treatment difference estimates of the percentage change from baseline with 95% confidence intervals.Results
Treatment with ERN/LRPT produced significantly greater improvements in Lp(a), ApoB, non-HDL-C, ApoA1, and ApoB/ApoA1 ratio compared with placebo/active comparator in each study. These effects were generally consistent across key subgroups within each study.Conclusion
ERN/LRPT produced lipid-altering efficacy on the parameters evaluated in four controlled studies; these effects were generally consistent across all examined subgroups. ERN/LRPT represents an effective and reliable therapeutic option for the treatment of dyslipidemia in a wide range of patient types.Clinical Trial Registration
Registered as Clinicaltrials.gov NCT00269204, NCT00269217, NCT00479388, and NCT00485758. 相似文献39.
40.